A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

DiObex Inc. is developing an experimental drug (DIO-902) that is made up of part of the ketoconazole molecule for the treatment of elevated blood glucose associated with type 2 diabetes mellitus. Ketoconazole (Nizoral®) is a drug available by prescription for the treatment of fungal infections however DIO-902 is an investigational drug. DIO-902 may lower blood glucose by lowering levels of a naturally occurring hormone called cortisol. Elevated cortisol may contribute to the development of type 2 diabetes.

The purpose of this research study is to test the safety of DIO-902 when taken by mouth with metformin and the cholesterol-lowering drug atorvastatin to determine the type and severity of any side effects from this treatment.

Other purposes of the study are to see how the treatment affects your blood glucose levels, cholesterol levels, blood pressure, and waist circumference.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

DIO-902 may lower blood glucose by lowering levels of a naturally occurring hormone called cortisol. Elevated cortisol may contribute to the development of type 2 diabetes. Clinical trials with ketoconazole have been carried out in patients with type 2 diabetes. Three clinical trials with DIO-902 have been completed in which 37 patients with type 2 diabetes and 42 normal healthy volunteers (people without type 2 diabetes) were enrolled. Patients in these studies received multiple doses of DIO-902. DIO-902 may reduce the level of cortisol in your blood and therefore may provide you with better control of your blood glucose levels.

STUDY DRUG ASSIGNMENT

You will be randomized, that is, given a 1 in 4 chance of receiving either 150mg/day of DIO-902, 300mg/day of DIO-902, 450mg/day of DIO-902 or DIO-902 placebo and a 1 in 2 chance of receiving 10mg/day of atorvastatin or atorvastatin placebo. The study drug is a tablet and will be taken by mouth with water. You will take 3 tablets of DIO-902 or DIO-902 placebo and 1 tablet of atorvastatin or atorvastatin placebo each day. The tablets will be taken at the same time each day (2200h or 10:00pm). Neither you nor your doctor will know which dose of DIO-902 or DIO-902 placebo you are on or whether you are taking the atorvastatin or atorvastatin placebo. If necessary, your doctor has a way of finding out which dose you were assigned.

Atorvastatin

If you are taking any cholesterol-lowering drugs, these drugs must be discontinued on the day prior to the Pre-Treatment Visit (Week -4) and for the duration of the study. At Visit 1 (Week 0) you will be assigned to DIO-902 or DIO-902 placebo and to either atorvastatin or atorvastatin placebo. You will continue to take the assigned drug until Study Visit 4 (Week 8). At Study Visit 4 (Week 8) all patients will begin taking atorvastatin through the remainder of the study. Your DIO-902 or DIO-902 placebo assignment will remain the same. Atorvastatin tablets will be supplied to you until Study Visit 6 (Week 16). At this visit you will be given a prescription for a 28 day supply of atorvastatin 10mg.day to last until Study Visit 7 (Week 20).

There will a total of 9 study visits. At each visit all or some of the following will occur: blood and urine samples will be taken, physical exam, assessment of side effects, and ECG will be performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

diabetes type 2 diabetes cholesterol

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

DIO-902 placebo + atorvastatin placebo

Group Type PLACEBO_COMPARATOR

DIO-902 placebo

Intervention Type DRUG

DIO-902 placebo tablet once daily for 16 weeks

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

A subject may be included in this study if he/she meets all of the following criteria:

1. Male or female, age 18 to 75
2. Females of childbearing potential (intact uterus and within 1 year since the last menstrual period) should be non-lactating and have a negative serum pregnancy test. In addition, these subjects should agree to use the following acceptable birth control methods beginning at the Screening Visit and throughout the study:

1. abstinence
2. surgical sterilization (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum
3. IUD in place for at least 3 months
4. barrier methods (condom or diaphragm) with spermicide
5. surgical sterilization of the partner (vasectomy for 6 months)
6. hormonal contraceptives for at least 3 months prior to the first dose
3. Diagnosis of type 2 diabetes mellitus (DM) for at least 6 months.
4. Type 2 diabetes may be treated only with metformin (metformin hydrochloride tablets or metformin hydrochloride extended-release tablets) at a total daily dose of 500 mg to the maximum labeled dose. (See Appendix G for List of Drug Trade Names).The dose of metformin must be stable for \>8 weeks prior to the Pre-Treatment Visit (Week -4) and throughout the course of the study. The subject must not be on any other pharmacologic or over-the-counter treatments for diabetes.
5. HbA1C level of 7.0 to 10.0%
6. Fasting C-peptide level of \>0.33 nmol/l (1.0 ng/ml)
7. ACTH stimulation test results with any cortisol level of \>18 µg/dl at baseline or 60 minutes
8. Normal complete blood count (CBC) with platelets and differential
9. 12-lead electrocardiogram (ECG) shows no acute ischemia or clinically significant abnormality. Subjects with QTc interval of \>450 msec will be excluded from the study.
10. BMI of 27 to 42 kg/m2 (see Appendix B)
11. Subjects with a history of hypertension may be on a stable anti-hypertensive regimen for (except those drugs stated under Exclusion Criterion 8) for \>6 weeks prior to the Pre-Treatment Visit (Week -4))
12. Ability to comprehend and a willingness to provide informed consent

Exclusion Criteria

* A subject may be excluded from this study if he/she meets any of the following criteria:

1. Previous participation in a clinical trial with DIO-902.
2. History of any atherosclerotic disorder (myocardial infarction, unstable angina, cerebrovascular accident, peripheral vascular disease or congestive heart failure secondary to ischemic myocardial injury) that would, in the estimation of the Investigator, make it unsafe to stop all lipid lowering drugs for up to 12 weeks during the course of the study.
3. Known hypersensitivity or idiosyncratic reaction related to ketoconazole or other imidazole compounds.
4. History of malignancy (except basal cell carcinoma) within the 3 years before the initial dose of the study medication.
5. Excessive alcohol intake (\>20 g per day for females (1.5 standard alcohol drinks) or \>30 g per day for males (2.0 standard alcohol drinks) (a standard drink contains 14 g of alcohol: 12 oz of beer, 5 oz of wine or 1.5 oz of spirits) or drug abuse. (1.0 fluid oz (US) = 29.57 ml)
6. Any other clinically significant medical condition, as determined by the Investigator. These clinically significant medical conditions include, but are not limited to, uncontrolled hypertension, NYHA class III or IV CHF, proliferative diabetic retinopathy and neuropathic symptoms that limit activities of daily living.
7. Participation in another clinical trial and/or treatment received with any investigational agent within one month before the initial dose of study medication.
8. Concomitant therapy with the following: (See Appendix G for List of Drug Trade Names)

1. weight loss medications
2. oral or injected hypoglycemics (metformin is allowed) or insulin
3. oral, parenteral or inhaled steroids; nasal, topical ocular, intravitreal, and low to moderate potency topical steroids are allowed
4. dihydropyridine calcium channel blockers (amlodipine, diltiazem and verapamil are allowed)
5. H2 antagonists and proton pump inhibitors (liquid and tablet antacids are allowed)
6. midazolam, triazolam, alprazolam, terfenadine, astemizole, digoxin, coumarin derivatives, phenytoin, rifampin, HIV protease inhibitors, spironolactone, aliskiren, erythromycin or clarithromycin, cyclosporine or tacrolimus
7. Subjects currently taking lipid lowering medications may be enrolled if the Investigator determines that the subject does not have any conditions that preclude cessation of lipid lowering treatment for up to 12 weeks. \[All subjects will be required to discontinue all lipid lowering therapies during the 4 week Pre-Treatment Period and will then be randomized to receive either atorvastatin 10 mg or atorvastatin placebo during the first 8 weeks of the Treatment Period. All subjects will then receive atorvastatin 10 mg during weeks 8 to 16 of the Treatment Period.\] Subjects may not be on any other lipid lowering agent through Visit 7 (Week 20) of the study.
9. History of HIV
10. Positive hepatitis B (HbsAg) or positive hepatitis C (Hepatitis C antibody) test during Screening
11. Liver function tests must not be above the following cut-offs: ALT and/or AST \>3.0X ULN, AP \>1.5X ULN and total bilirubin \>ULN. (If all LFTs are WNL and total bilirubin is elevated, a retest of direct and indirect bilirubin may be performed. Subjects with indirect total bilirubin up to 3X ULN (presumed Gilbert's syndrome) may be enrolled if all other LFTs are WNL.)
12. CK must not be \>2.5X ULN if not clearly related to recent exercise, injury or unusual activity
13. Creatinine must not be \>1.4 mg/dl in females and \>1.5 mg/dl in males.
14. Thyroid stimulating hormone level \>1.5X ULN
15. History of lactic acidosis
16. Known hypersensitivity to cosyntropin (ACTH) or any component of the formulation (mannitol or sodium chloride)
17. Known intolerance to statin drugs
18. Any other condition which increases the risk of participation in the trial in the opinion of the investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

DiObex, Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sherwyn Schwartz, MD

Role: PRINCIPAL_INVESTIGATOR

Diabetes & Glandular Disease Research Associates

Review additional registry numbers or institutional identifiers associated with this trial.

DIO-502

Identifier Type: -

Identifier Source: org_study_id

A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

1

DIO-902

2

DIO-902

3

DIO-902

4

DIO-902 placebo

5

DIO-902

6

DIO-902

7

DIO-902

8

DIO-902 placebo

Interventions

DIO-902

DIO-902

DIO-902

DIO-902 placebo

DIO-902

DIO-902

DIO-902

DIO-902 placebo

Other Intervention Names

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

DiObex

Responsible Party

Principal Investigators

Sherwyn Schwartz, MD

Locations

Dr. Terence Hart

Genova Research

Research Solutions

Arkansas Primary Care Clinic

Advanced Medical Research

Mills-Peninsula Helath Services

Diabetes Research Goup University of Hawaii at Manoa

Creighton Diabetes Center

AHS Oklahoma Physician Group

Covance Clinical Research Unit - Dr. Andrew Ahmann

Covance CRU

Diabetes Glandular and Disease Research Associates

Flinders Medical Centre

Lyell McEwin Hospital

ECRU

School of Medicine and Pharmacology

Keough Institute

Endocrinology Research Unit

Endocrinology Department

Royal Melbourn Hospital

Middlemore Hospital

Lipid and Diabetes Research

Waikaito Hospital

Diabetes Centre

Countries

Other Identifiers

DIO-502